NCT04478825View on ClinicalTrials.gov

Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis

PHASE1TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

August 4, 2021

Study Completion Date

August 24, 2021

Conditions
Ulcerative Colitis
Interventions
DRUG

BBT-401-1S

BBT-401-1S, 8 weeks, once a day

Trial Locations (2)

Unknown

P3 Research, Tauranga

P3 Research, Wellington

Sponsors

Collaborators (1)

Covance
All Listed Sponsors
collaborator

Covance

INDUSTRY

lead

Bridge Biotherapeutics, Inc.

INDUSTRY

NCT04478825 - Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis | Biotech Hunter | Biotech Hunter